All areas are being treated (glabellar,canthal, frontalis, lip flip ...) although only glabellar lines is the indication for which the FDA gave the approval.
I wonder if the same will be the case for the clinical indications - i.e. once we get the nod for cervical dystonia, will docs use it off-label for upper limb spasticity, lower limb, over active bladder, migrane etc. Any thoughts?
Market Data 
Markets 
AI
